Show simple item record

dc.contributor.authorSchiller, Meinhard
dc.contributor.authorMetze, Dieter
dc.contributor.authorLuger, Thomas A
dc.contributor.authorGrabbe, Stephan
dc.contributor.authorGunzer, Matthias
dc.date.accessioned2007-11-15T12:33:05Z
dc.date.available2007-11-15T12:33:05Z
dc.date.issued2006-05-01
dc.identifier.citationExp. Dermatol. 2006, 15(5):331-41en
dc.identifier.issn0906-6705
dc.identifier.pmid16630072
dc.identifier.doi10.1111/j.0906-6705.2006.00414.x
dc.identifier.urihttp://hdl.handle.net/10033/14580
dc.description.abstractThe innate immune system governs the interconnecting pathways of microbial recognition, inflammation, microbial clearance, and cell death. A family of evolutionarily conserved receptors, known as the Toll-like receptors (TLRs), is crucial in early host defense against invading pathogens. Upon TLR stimulation, nuclear factor-kappaB activation and the interferon (IFN)-regulatory factor 3 pathway initiate production of pro-inflammatory cytokines, such as interleukin-1 and tumor necrosis factor-alpha, and production of type I IFNs (IFN-alpha and IFN-beta), respectively. The innate immunity thereby offers diverse targets for highly selective therapeutics, such as small molecular synthetic compounds that modify innate immune responses. The notion that activation of the innate immune system is a prerequisite for the induction of acquired immunity raised interest in these immune response modifiers as potential therapeutics for viral infections and various tumors. A scenario of dermal events following skin cancer treatment with imiquimod presumably comprises (i) an initial low amount of pro-inflammatory cytokine secretion by macrophages and dermal dendritic cells (DCs), thereby (ii) attracting an increasing number type I IFN-producing plasmacytoid DCs (pDCs) from the blood; (iii) Langerhans cells migrate into draining lymph nodes, leading to an increased presentation of tumor antigen in the draining lymph node, and (iv) consequently an increased generation of tumor-specific T cells and finally (v) an accumulation of tumoricidal effector cells in the treated skin area. The induction of predominately T helper (Th)1-type cytokine profiles by TLR agonists such as imiquimod might have further benefits by shifting the dominant Th2-type response in atopic diseases such as asthma and atopic dermatitis to a more potent Th1 response.
dc.format.extent186682 bytes
dc.format.extent2692655 bytes
dc.format.extent2405021 bytes
dc.format.extent41178733 bytes
dc.format.extent3362012 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.titleImmune response modifiers--mode of action.en
dc.typeArticleen
dc.format.digYES
refterms.dateFOA2018-06-12T22:57:59Z
html.description.abstractThe innate immune system governs the interconnecting pathways of microbial recognition, inflammation, microbial clearance, and cell death. A family of evolutionarily conserved receptors, known as the Toll-like receptors (TLRs), is crucial in early host defense against invading pathogens. Upon TLR stimulation, nuclear factor-kappaB activation and the interferon (IFN)-regulatory factor 3 pathway initiate production of pro-inflammatory cytokines, such as interleukin-1 and tumor necrosis factor-alpha, and production of type I IFNs (IFN-alpha and IFN-beta), respectively. The innate immunity thereby offers diverse targets for highly selective therapeutics, such as small molecular synthetic compounds that modify innate immune responses. The notion that activation of the innate immune system is a prerequisite for the induction of acquired immunity raised interest in these immune response modifiers as potential therapeutics for viral infections and various tumors. A scenario of dermal events following skin cancer treatment with imiquimod presumably comprises (i) an initial low amount of pro-inflammatory cytokine secretion by macrophages and dermal dendritic cells (DCs), thereby (ii) attracting an increasing number type I IFN-producing plasmacytoid DCs (pDCs) from the blood; (iii) Langerhans cells migrate into draining lymph nodes, leading to an increased presentation of tumor antigen in the draining lymph node, and (iv) consequently an increased generation of tumor-specific T cells and finally (v) an accumulation of tumoricidal effector cells in the treated skin area. The induction of predominately T helper (Th)1-type cytokine profiles by TLR agonists such as imiquimod might have further benefits by shifting the dominant Th2-type response in atopic diseases such as asthma and atopic dermatitis to a more potent Th1 response.


Files in this item

Thumbnail
Name:
Schiller_final.pdf
Size:
182.3Kb
Format:
PDF
Description:
original document
Thumbnail
Name:
EXD_05_153_figure1.pdf
Size:
2.567Mb
Format:
PDF
Description:
figure1
Thumbnail
Name:
EXD_05_153_figure2.pdf
Size:
2.293Mb
Format:
PDF
Description:
figure 2
Thumbnail
Name:
EXD_05_153_figure3.pdf
Size:
39.27Mb
Format:
PDF
Description:
figure 3
Thumbnail
Name:
EXD_05_153_figure4.pdf
Size:
3.206Mb
Format:
PDF
Description:
figure 4

This item appears in the following Collection(s)

Show simple item record